JP2012521364A - 概日リズムを調整する方法 - Google Patents

概日リズムを調整する方法 Download PDF

Info

Publication number
JP2012521364A
JP2012521364A JP2012501029A JP2012501029A JP2012521364A JP 2012521364 A JP2012521364 A JP 2012521364A JP 2012501029 A JP2012501029 A JP 2012501029A JP 2012501029 A JP2012501029 A JP 2012501029A JP 2012521364 A JP2012521364 A JP 2012521364A
Authority
JP
Japan
Prior art keywords
ampk
circadian rhythm
circadian
agonist
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012501029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521364A5 (https=
Inventor
ロナルド エバンス，
カッジャ エー． ラミア，
リューベン ジェイ． シャー，
ルチアーノ ディタッチオ，
サチダナンダ パンダ，
ウマ エム． サチデバ，
クレイグ ビー． トンプソン，
Original Assignee
ザ ソーク インスティテュート フォー バイオロジカル スタディーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ソーク インスティテュート フォー バイオロジカル スタディーズ filed Critical ザ ソーク インスティテュート フォー バイオロジカル スタディーズ
Publication of JP2012521364A publication Critical patent/JP2012521364A/ja
Publication of JP2012521364A5 publication Critical patent/JP2012521364A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2864—Sleep disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012501029A 2009-03-20 2010-03-22 概日リズムを調整する方法 Pending JP2012521364A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16222509P 2009-03-20 2009-03-20
US61/162,225 2009-03-20
PCT/US2010/028155 WO2010108179A1 (en) 2009-03-20 2010-03-22 Methods for modulating circadian rythms

Publications (2)

Publication Number Publication Date
JP2012521364A true JP2012521364A (ja) 2012-09-13
JP2012521364A5 JP2012521364A5 (https=) 2013-05-09

Family

ID=42740034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012501029A Pending JP2012521364A (ja) 2009-03-20 2010-03-22 概日リズムを調整する方法

Country Status (6)

Country Link
US (1) US20120264796A1 (https=)
EP (1) EP2409152A4 (https=)
JP (1) JP2012521364A (https=)
AU (1) AU2010226417A1 (https=)
CA (1) CA2753876A1 (https=)
WO (1) WO2010108179A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521198A (ja) * 2009-03-20 2012-09-13 ザ ソーク インスティテュート フォー バイオロジカル スタディーズ 代謝リズムおよび概日リズムを調整する方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186306A1 (en) * 2012-09-28 2014-07-03 Paul Ronald Plante Novel ampk agonist compositions and methods of use
US10572904B2 (en) 2017-03-29 2020-02-25 International Business Machines Corporation Micro circadian rhythms driven dynamic product offering adjustment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213295A1 (en) * 2006-01-16 2007-09-13 The Board Of Regents Of The University Of Texas System Methods and compositions for inducing torpor in a subject
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3466215D1 (en) * 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
US20060147947A1 (en) * 2002-12-04 2006-07-06 Javier Apfeld AMPK pathway components
CA2551637A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
TWI428767B (zh) * 2006-06-26 2014-03-01 Ibm 最佳化配置系統參數集之方法，程式及裝置
KR100766273B1 (ko) * 2006-10-23 2007-10-15 주식회사 녹십자 아디포넥틴을 유효 성분으로 포함하는 프라더-윌리 증후군소아용 수면 장애 치료제
CA2710764A1 (en) * 2007-12-28 2009-07-09 The Salk Institute For Biological Studies Methods for enhancing muscle performance and tone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213295A1 (en) * 2006-01-16 2007-09-13 The Board Of Regents Of The University Of Texas System Methods and compositions for inducing torpor in a subject
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6014015802; Ａｍ．　Ｊ．　Ｐｈｙｓｉｏｌ．　Ｅｎｄｏｃｒｉｎｏｌ．　Ｍｅｔａｂ．，　２００８，　Ｖｏｌ．２９５，　Ｎｏ．５，　ｐｐ．Ｅ１０３２-Ｅ１０３７ *
JPN6014015804; Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ．，　２００７，　Ｖｏｌ．２８２，　Ｎｏ．２９，　ｐｐ．２０７９４-２０７９８ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521198A (ja) * 2009-03-20 2012-09-13 ザ ソーク インスティテュート フォー バイオロジカル スタディーズ 代謝リズムおよび概日リズムを調整する方法

Also Published As

Publication number Publication date
US20120264796A1 (en) 2012-10-18
EP2409152A1 (en) 2012-01-25
EP2409152A4 (en) 2012-10-17
CA2753876A1 (en) 2010-09-23
WO2010108179A1 (en) 2010-09-23
AU2010226417A1 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
Agarwal et al. PTEN-induced kinase 1 (PINK1) and Parkin: Unlocking a mitochondrial quality control pathway linked to Parkinson's disease
Forrestel et al. Chronomedicine and type 2 diabetes: shining some light on melatonin
Tahara et al. Chrono-biology, chrono-pharmacology, and chrono-nutrition
Jagannath et al. The multiple roles of salt-inducible kinases in regulating physiology
Boone et al. Traumatic brain injury-induced dysregulation of the circadian clock
CN106459079B (zh) 青蒿素化合物及桥蛋白激动剂的医疗用途
Zelkas et al. Serotonin-secreting enteroendocrine cells respond via diverse mechanisms to acute and chronic changes in glucose availability
Natalicchio et al. Irisin increases the expression of anorexigenic and neurotrophic genes in mouse brain
US20120134985A1 (en) Methods for modulating metabolic and circadian rhythms
WO2011121109A1 (en) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
KR20150010793A (ko) 열 충격 단백질 (hsp) 90-베타의 조절에 의한 대사 증후군의 치료 방법들
Smith et al. eEF2K regulates pain through translational control of BDNF
Durumutla et al. Glucocorticoid chronopharmacology promotes glucose metabolism in heart through a cardiomyocyte-autonomous transactivation program
Osaka et al. Luseogliflozin inhibits high glucose-induced TGF-β 2 expression in mouse cardiomyocytes by suppressing NHE-1 activity
Bhatia et al. Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27Kip1 localization
US20110047633A1 (en) Control of Exocrine Pancreatic Function Using Bone Morphogenetic Proteins
JP2012521364A (ja) 概日リズムを調整する方法
Liu et al. Decreased hyperpolarization-activated cyclic nucleotide-gated channels are involved in bladder dysfunction associated with spinal cord injury
Dong et al. Ckip-1 3’UTR alleviates prolonged sleep deprivation induced cardiac dysfunction by activating CaMKK2/AMPK/cTNI pathway
Cao et al. Licochalcone E improves insulin sensitivity in palmitic acid-treated HepG2 cells through inhibition of the NLRP3 signaling pathway
No et al. Effect of chronic alcohol intake on the expression of muscle atrophy-related proteins in growing rats
Costa A concise overview of circadian timing in Drosophila
Hadley et al. The focal adhesion kinases regulate leptin action and the weight reducing effect of HDAC6 inhibition
Kumar Trace amine-associated receptor 1 activation regulates glucose-dependent insulin secretion in pancreatic beta cells in vitro
Durumutla et al. Glucocorticoid chrono-pharmacology unveils novel targets for the cardiomyocyte-specific GR-KLF15 axis in cardiac glucose metabolism

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140416

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140922